Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

Markets & Finance

Pacific Growth Keeps 'Overweight' on Corixa


Pacific Growth keeps its overweight rating on Corixa (CRXA).

Analyst Thomas Dietz says with the FDA approving Corixa's Bexxar drug on Monday, success in Phase IV trials for Bexxar is not required for the drug to remain on the market. Dietz says Corixa indicated it will get a milestone payment from GlaxoSmithKline as a result of the approval. He thinks Bexxar has the opportunity to be proven as a potential first-line therapy for non-Hodgkin's lymphoma -- potentially doubling the size of Corixa's market.

Dietz also thinks the Bexxar approval will lead to Wall Street paying closer attention to Corixa's promising pipeline. This includes treatments for cancer, autoimmune vaccines and their adjuvants, as well as research with molecules known as AGP that create compounds to ward off infections. He sees a $1.29 2003 per-share loss.


LIMITED-TIME OFFER SUBSCRIBE NOW
 
blog comments powered by Disqus